Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Jun Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7858-8260; OpenAlex author ID A5022169204. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1038/s41401-024-01403-8↗
  2. An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft. First author DOI 10.1038/s41401-022-00960-0↗
  3. CYLD deficiency promotes pancreatic cancer development by causing mitotic defects. Co-author DOI 10.1002/jcp.27658↗
  4. EB1 phosphorylation mediates the functions of ASK1 in pancreatic cancer development. Last author DOI 10.18632/oncotarget.21004↗
  5. Cep70 overexpression stimulates pancreatic cancer by inducing centrosome abnormality and microtubule disorganization. Co-author DOI 10.1038/srep21263↗
  6. Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer. Last author DOI 10.18632/oncotarget.12090↗
  7. Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells. Last author DOI 10.1007/s13238-013-0010-3↗
  8. Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Co-author DOI 10.4161/cbt.21412↗
  9. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Last author DOI 10.1038/aps.2011.130↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junsheng Xue · 2 shared papers, 2023–2025 · strength 0.44
  2. Qingyu Yao · 2 shared papers, 2023–2025 · strength 0.44
  3. Min Liu · 7 shared papers, 2011–2019 · strength 0.38
  4. Dengwen Li · 6 shared papers, 2012–2019 · strength 0.36
  5. Tianyan Zhou · 1 shared paper, 2025 · strength 0.26
  6. Songbo Xie · 4 shared papers, 2013–2019 · strength 0.25
  7. Ye Yao · 1 shared paper, 2023 · strength 0.18
  8. Tianyan Zhou · 1 shared paper, 2023 · strength 0.18
  9. Youguang Luo · 3 shared papers, 2011–2017 · strength 0.16
  10. Siqi Gao · 2 shared papers, 2016–2017 · strength 0.13
  11. Xiaodong Sun · 3 shared papers, 2011–2013 · strength 0.10
  12. Shiyu Liu · 1 shared paper, 2016 · strength 0.06
  13. Chao Zhang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.